If pharmacological interventions can disrupt lipid raft-dependent signaling cascades, this approach holds promise for reversing the immunosuppressive microenvironment in CRC and enhancing the sensitivity of MSS-type patients to PD-1/PD-L1 antibody therapy. Here, PDCD1 is linked to colorectal carcinoma.